EMA Authorised: Tocilizumab STADA (previously Tofidence) (tocilizumab) — STADA Arzneimittel AG

View source ↗

Summary

EMA authorised STADA's tocilizumab product (Tocilizumab STADA) for rheumatoid arthritis, juvenile idiopathic arthritis, and COVID-19 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• Tocilizumab STADA (tocilizumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;COVID-19 virus infection;Arthritis, Juvenile Rheumatoid. MAH: STADA Arzneimittel AG. Decision date: 15/01/2026